Search Results - "IYER, Renuka"

Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors by Iyer, Renuka V., Konda, Bhavana, Fountzilas, Christos, Mukherjee, Sarbajit, Owen, Dwight, Attwood, Kristopher, Wang, Chong, Suffren, Sheryl‐Ann, Hicks, Karen, Wilton, John, Bies, Robert, Casucci, Danielle, Reidy‐Lagunes, Diane, Shah, Manisha

“…Background Antiangiogenic‐targeting agents have low response rates in patients with nonpancreatic neuroendocrine tumors (NETs). Nintedanib is an oral…”
Get full text

Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma by Juloori, Aditya, Katipally, Rohan R., Lemons, Jeffrey M., Singh, Anurag K., Iyer, Renuka, Robbins, Jared R., George, Ben, Hall, William A., Pitroda, Sean P., Arif, Fauzia, Fung, John, Pillai, Anjana, Liao, Chih-Yi, Sharma, Manish, Liauw, Stanley L.

“…Immunotherapy has emerged as a promising therapeutic option for advanced or unresectable hepatocellular carcinoma (HCC). However, survival remains poor with…”
Get full text

Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells by Iyer, Renuka V, Maguire, Orla, Kim, Minhyung, Curtin, Leslie I, Sexton, Sandra, Fisher, Daniel T, Schihl, Sarah A, Fetterly, Gerald, Menne, Stephan, Minderman, Hans

“…The multikinase inhibitor sorafenib is the only standard first-line therapy for hepatocellular carcinoma (HCC). Here, we report the dose-dependent effects of…”
Get full text

Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers by Bharthuar, Anubha, Khorana, Alok A, Hutson, Alan, Wang, Jian-Guo, Key, Nigel S, Mackman, Nigel, Iyer, Renuka V

“…Abstract Background Tissue factor (TF), the physiologic initiator of coagulation, is over-expressed in pancreatic cancer, and is associated with a…”
Get full text

Sorafenib: a clinical and pharmacologic review by Iyer, Renuka, Fetterly, Gerald, Lugade, Amit, Thanavala, Yasmin

“…Sorafenib is an oral receptor tyrosine kinase inhibitor that inhibits Raf serine/threonine kinases and receptor tyrosine kinases (vascular endothelial growth…”
Get more information

A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma by Fountzilas, Christos, Gupta, Medhavi, Lee, Sunyoung, Krishnamurthi, Smitha, Estfan, Bassam, Wang, Katy, Attwood, Kristopher, Wilton, John, Bies, Robert, Bshara, Wiam, Iyer, Renuka

“…Background Hepatocellular carcinoma (HCC) is a major cause of cancer-related death. It is a highly vascular tumour with multiple angiogenic factors, most…”
Get full text

Hepatocellular Carcinoma: Special Issue Highlights by Gupta, Medhavi, Iyer, Renuka V.

“…[...]…”
Get full text

TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial by Boland, Patrick M., Mukherjee, Sarbajit, Imanirad, Iman, Vijayvergia, Namrata, Cohen, Seth D., Gupta, Medhavi, Iyer, Renuka V., Bakin, Andrei, Wang, Jianxin, Chatley, Sarah, Cahill, Beth, Vadehra, Deepak, Attwood, Kristopher, Hochster, Howard S., Fountzilas, Christos

“…Background The efficacy of FOLFIRI plus an antiangiogenesis biologic agent as 2nd line therapy for metastatic colorectal adenocarcinoma is limited. TAS-102 is…”
Get full text

Current Understanding of the Molecular Biology of Pancreatic Neuroendocrine Tumors by JIANLIANG ZHANG, FRANCOIS, Rony, IYER, Renuka, SESHADRI, Mukund, ZAJAC-KAYE, Maria, HOCHWALD, Steven N

“…Pancreatic neuroendocrine tumors (PanNETs) are complicated and often deadly neoplasms. A recent increased understanding of their molecular biology has…”
Get full text

Clinicopathological characteristics and outcomes of rare histologic subtypes of gallbladder cancer over two decades: A population-based study by Samuel, Sandeep, Mukherjee, Sarbajit, Ammannagari, Nischala, Pokuri, Venkata K, Kuvshinoff, Boris, Groman, Adrienne, LeVea, Charles M, Iyer, Renuka

“…There is limited literature about the clinicopathological characteristics and outcomes of rare histologic variants of gallbladder cancer (GBC). Using SEER…”
Get full text

Tivozanib mediated inhibition of c-Kit/SCF signaling on Tregs and MDSCs and reversal of tumor induced immune suppression correlates with survival of HCC patients by Kalathil, Suresh Gopi, Wang, Katy, Hutson, Alan, Iyer, Renuka, Thanavala, Yasmin

“…The immune modulatory effect of tivozanib, a tyrosine kinase inhibitor, and the underlying immune mechanisms impacting survival of HCC patients have not been…”
Get full text

Evaluation of the serotonin pathway as a biomarker in cholangiocarcinoma by Fountzilas, Christos, Velasco, Sylvia Alarcon, Bshara, Wiam, LeVea, Charles M, Gupta, Medhavi, Ji, Wenyan, George, Anthony, Attwood, Kristopher, Iyer, Renuka V

“…Cholangiocarcinomas (CCAs) are rare and aggressive malignant tumors of the biliary tract. Serotonin (5HT) has tumor-promoting effects in CCA while inhibition…”
Get full text

Updates in Biliary Tract Cancers by Li, Daneng, Zhang, Ya-Han, Crook, Christiana J, Iyer, Renuka V

“…Biliary tract cancers (BTCs) are a heterogeneous group of malignancies arising from the epithelium of the biliary tree [...]…”
Get full text

A Translational Hepatic Artery Infusion (HAI) Model for Hepatocellular Carcinoma in Woodchucks by Kim, Minhyung, Powers, Colin A., Curtin, Leslie I., Fisher, Daniel T., Sexton, Sandra, Gurova, Katerina V., Skitzki, Joseph J., Iyer, Renuka V.

“…Woodchucks (Marmota monax) are a well-accepted animal model for the investigation of spontaneous hepatocellular carcinoma (HCC). As HCC tumors obtain nutrient…”
Get full text

A phase I/II study of nintedanib and capecitabine for refractory metastatic colorectal cancer by Boland, Patrick M, Ebos, John M L, Attwood, Kristopher, Mastri, Michalis, Fountzilas, Christos, Iyer, Renuka V, Banker, Christopher, Goey, Andrew K L, Bies, Robert, Ma, Wen Wee, Fakih, Marwan

“…Nintedanib is a tyrosine kinase inhibitor with efficacy in bevacizumab-resistant colorectal cancer models. This phase I/II study evaluated the recommended…”
Get full text

Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection by Balsitis, Scott, Gali, Volodymyr, Mason, Pamela J, Chaniewski, Susan, Levine, Steven M, Wichroski, Michael J, Feulner, Michael, Song, Yunling, Granaldi, Karen, Loy, James K, Thompson, Chris M, Lesniak, Jacob A, Brockus, Catherine, Kishnani, Narendra, Menne, Stephan, Cockett, Mark I, Iyer, Renuka, Mason, Stephen W, Tenney, Daniel J

“…Immune clearance of Hepatitis B virus (HBV) is characterized by broad and robust antiviral T cell responses, while virus-specific T cells in chronic hepatitis…”
Get full text

Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature by Gupta, Medhavi, Sherrow, Christopher, Krone, Maghan E, Blais, Edik M, Pishvaian, Michael J, Petricoin, Emanuel F, Matrisian, Lynn M, DeArbeloa, Patricia, Gregory, Gary, Brown, Alyson, Zalewski, Olivia, Prinzing, Gillian, Roche, Charles, Kanehira, Kazunori, Mukherjee, Sarbajit, Iyer, Renuka, Fountzilas, Christos

“…Pancreatic acinar cell carcinoma (PACC) is a rare pancreatic exocrine malignancy. Compared with the more common pancreatic ductal adenocarcinoma (PDAC), PACC…”
Get more information

Demographic Characteristics and Survival in Young-Onset Colorectal Neuroendocrine Neoplasms by Vadehra, Deepak, Sonti, Sahithi, Siromoni, Beas, Ramesh, Mrinalini, Mukhopadhyay, Debduti, Groman, Adrienne, Iyer, Renuka, Mukherjee, Sarbajit

“…Recent epidemiological studies have revealed an upward trend in young-onset colorectal cancer (YOCRC) overall, whereas specific data on young-onset colorectal…”
Get full text

A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer by Iyer, Renuka V, Pokuri, Venkata K, Groman, Adrienne, Ma, Wen W, Malhotra, Usha, Iancu, Dan M, Grande, Catherine, Saab, Tanios B

“…Vascular endothelial growth factor overexpression, seen in 42% to 76% of biliary tract cancers (BTCs), correlates with poor survival. We explored the…”
Get full text

Gallbladder cancer: Defining the indications for primary radical resection and radical re-resection by Foster, Jason M, Hoshi, Hisakazu, Gibbs, John F, Iyer, Renuka, Javle, Miland, Chu, Quyen, Kuvshinoff, Boris

“…The role of radical resection for gallbladder cancer is an ongoing area of debate. In this review, we present our experience managing gallbladder cancer at a…”
Get full text